Company Overview and News

 
BMRN / BioMarin Pharmaceutical, Inc. S-8 POS

2018-08-22 sec.gov
S-8 POS Registration No. 333-85368 Registration No. 333-84787 As filed with the Securities and Exchange Commission on August 22, 2018
BMRN

 
BMRN / BioMarin Pharmaceutical, Inc. S-8 POS

2018-08-22 sec.gov
S-8 POS Registration No. 333-85368 Registration No. 333-84787 As filed with the Securities and Exchange Commission on August 22, 2018
BMRN

24
CORRECTED--Express Scripts staking out million dollar gene therapies

2018-08-15 reuters - 1
(Reuters) - Express Scripts Holding Co (ESRX.O) built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
RPT-FOCUS-Express Scripts staking out million dollar gene therapies

2018-08-15 reuters
Aug 15 (Reuters) - Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
RPT-FOCUS-Express Scripts staking out million dollar gene therapies

2018-08-15 reuters
Aug 15 (Reuters) - Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
Express Scripts staking out million dollar gene therapies

2018-08-15 channelnewsasia
Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

23
Express Scripts staking out million dollar gene therapies

2018-08-15 reuters
(Reuters) - Express Scripts Holding Co (ESRX.O) built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
BIIB NVS BLUE CI CVS UNH BMRN ONCE

3
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%

2018-08-08 zacks
BioMarin Pharmaceutical Inc. (BMRN - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $97.95 to $103.92 in the past one-month time frame.
VREX ELY IPGP RYB BMRN CBM

24
Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation

2018-08-08 seekingalpha - 1
The overall bioscience market traded up significantly today due to many upbeat earnings. A good number of equities under our coverage rallied due to their strong Q2 earnings.
NKTR IBB XBI ONCE BMRN

5
BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat

2018-08-03 zacks - 1
BioMarin Pharmaceutical Inc. (BMRN - Free Report) reported lower-than-expected earnings for the second quarter of 2018 but beat estimates for sales.
CY AERI PFE BMRN SNY

 
BMRN / BioMarin Pharmaceutical, Inc. 10-Q (Quarterly Report)

2018-08-03 sec.gov
bmrn-10q_20180630.htm UNITED
BMRN

1
BioMarin Pharmaceutical (BMRN) Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Tracy.
PFZ MS 500680 PFE PFIZER BMRN

 
BioMarin Pharmaceutical (BMRN) Q2 Earnings Miss Estimates

2018-08-02 zacks
BioMarin Pharmaceutical (BMRN - Free Report) just came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
SHAK BMRN

 
BMRN / BioMarin Pharmaceutical, Inc. 8-K (Current Report)

2018-08-02 sec.gov
bmrn-8k_20180802.htm
BMRN

48
Top Analyst Upgrades and Downgrades: Athenahealth, Illumina, Northrop Grumman, Square, Twitter, Yamana Gold and More

2018-07-31 247wallst - 1
Stocks were indicated to open marginally higher on Tuesday morning after a larger sell-off on Monday. Investors have been having less success buying the stock market dips in 2018 than in prior years. Many investors also are reconsidering how they want their investments positioned ahead of the midterm elections and during international trade concerns.
NTRI DB SQNXF YRI CHKVP NOV ILMN CHKDH CHKVZ CHKDG NOC TJX CHKDJ CHKDP AUY TWTR CKRGZ SQ BMRN CHKWZ ALLY CHK.WI CHK TRI ATHN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to BMRN / BioMarin Pharmaceutical, Inc. on message board site Silicon Investor.

BMRN - Biomarin Pharmaceutical Inc. BMRN - Biomarin Pharmaceutical Inc. BMRN - Biomarin Pharmaceutical Inc.
CUSIP: 09061G101